title: Randomized prospective study of the benefit of adjuvant radiation therapy in the treatment of soft tissue sarcomas of the extremity.
abstract: OBJECTIVE
  This randomized, prospective study assesses the impact of postoperative external-beam radiation therapy on local recurrence (LR), overall survival (OS), and quality of life after limb-sparing resection of extremity sarcomas.
  
  
  METHODS
  Patients with extremity tumors and a limb-sparing surgical option were randomized to receive or not receive postoperative adjuvant external-beam radiotherapy. Patients with high-grade sarcomas received postoperative adjuvant chemotherapy whereas patients with low-grade sarcomas or locally aggressive nonmalignant tumors were randomized after surgery alone.
  
  
  RESULTS
  Ninety-one patients with high-grade lesions were randomized; 47 to receive radiotherapy (XRT) and 44 to not receive XRT. With a median follow-up of 9.6 years, a highly significant decrease (P2 = .0028) in the probability of LR was seen with radiation, but no difference in OS was shown. Of 50 patients with low-grade lesions (24 randomized to resection alone and 26 to resection and postoperative XRT), there was also a lower probability of LR (P2 = .016) in patients receiving XRT, again, without a difference in OS. A concurrent quality-of-life study showed that extremity radiotherapy resulted in significantly worse limb strength, edema, and range of motion, but these deficits were often transient and had few measurable effects on activities of daily life or global quality of life.
  
  
  CONCLUSIONS
  This study indicates that although postoperative external-beam radiotherapy is highly effective in preventing LRs, selected patients with extremity soft tissue sarcoma who have a low risk of LR may not require adjuvant XRT after limb-sparing surgery (LSS).
authors.affiliation: Surgery Branch, National Cancer Institute, Bethesda, MD 20892, USA. jcyang@NCI.NIH.gov
authors.forename: J C
authors.initials: JC
authors.lastname: Yang
authors.forename: A E
authors.initials: AE
authors.lastname: Chang
authors.forename: A R
authors.initials: AR
authors.lastname: Baker
authors.forename: W F
authors.initials: WF
authors.lastname: Sindelar
authors.forename: D N
authors.initials: DN
authors.lastname: Danforth
authors.forename: S L
authors.initials: SL
authors.lastname: Topalian
authors.forename: T
authors.initials: T
authors.lastname: DeLaney
authors.forename: E
authors.initials: E
authors.lastname: Glatstein
authors.forename: S M
authors.initials: SM
authors.lastname: Steinberg
authors.forename: M J
authors.initials: MJ
authors.lastname: Merino
authors.forename: S A
authors.initials: SA
authors.lastname: Rosenberg
mesh_terms: D005121:Extremities; D005260:Female; D005500:Follow-Up Studies; D006801:Humans; D008297:Male; D009364:Neoplasm Recurrence, Local / Q000517:prevention & control*; D011446:Prospective Studies; D011788:Quality of Life; D018714:Radiotherapy, Adjuvant; D012509:Sarcoma / Q000532:radiotherapy* / Q000601:surgery*